| Target Price | $214.20 |
| Price | $169.97 |
| Potential |
26.02%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Astera Labs 2026 .
The average Astera Labs target price is $214.20.
This is
26.02%
register free of charge
$288.75
69.88%
register free of charge
$156.55
7.90%
register free of charge
|
|
| A rating was issued by 26 analysts: 21 Analysts recommend Astera Labs to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Astera Labs stock has an average upside potential 2026 of
26.02%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 396.29 | 847.85 |
| 242.25% | 113.95% | |
| EBITDA Margin | -28.49% | 34.90% |
| 19.01% | 222.49% | |
| Net Margin | -21.05% | 36.09% |
| 7.18% | 271.45% |
23 Analysts have issued a sales forecast Astera Labs 2025 . The average Astera Labs sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Astera Labs EBITDA forecast 2025. The average Astera Labs EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Astera Labs Analysts have issued a net profit forecast 2025. The average Astera Labs net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.64 | 1.81 |
| 276.47% | 382.81% | |
| P/E | 93.83 | |
| EV/Sales | 32.52 |
23 Analysts have issued a Astera Labs forecast for earnings per share. The average Astera Labs EPS is
This results in the following potential growth metrics and future valuations:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Northland Capital Markets |
Locked
➜
Locked
|
Locked | Dec 09 2025 |
| BNP Paribas Exane |
Locked
➜
Locked
|
Locked | Nov 20 2025 |
| Northland Capital Markets |
Locked
➜
Locked
|
Locked | Nov 17 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Roth Capital |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Northland Capital Markets:
Locked
➜
Locked
|
Dec 09 2025 |
|
Locked
BNP Paribas Exane:
Locked
➜
Locked
|
Nov 20 2025 |
|
Locked
Northland Capital Markets:
Locked
➜
Locked
|
Nov 17 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
Roth Capital:
Locked
➜
Locked
|
Nov 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


